Article
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Cancer - 1 Apr 2009
Peeters Marc, Siena Salvatore, Van Cutsem Eric, Sobrero Alberto, Hendlisz Alain, Cascinu Stefano, Kalofonos Haralabos, Devercelli Giovanna, Wolf Michael, Amado Rafael G
Abstract excerpt
BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient-reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of panitumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorectal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.